Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908073 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29477078 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29352152 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2551441 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486191 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30147576 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486209 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL119400 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL31610887 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL7822425 | 0.93 | CASP3 (0.54) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030887-A1 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | SYSTIMMUNE, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030887-A1 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | CD47, ANPEP, NGLY1 | CASP3 1236/4885MDM4 3653/4885TP53 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.